Archives — December 2017 back to current month (61)
Technical analyst Clive Maund delves into the reasons behind copper's recent rise and what that could mean for silver.
When to Take Profits in the Cannabis Sector (12/28/2017)
With a run-up in cannabis stocks, technical analyst Clive Maund shares his thoughts on when investors should take profits.
2017: A Year of Triple Digit Stock Performance (12/28/2017)
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases.
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease.
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect.
Jack Chan's Weekly Precious Metals Market Update (12/27/2017)
Technical analyst Jack Chan charts the latest movements in the gold and silver markets, noting an upturn in the cycle that might indicate the end of a multimonth correction.
BMO Capital Markets reported on this company's recent royalty transaction and its upside potential.
Precious metals expert Michael Ballanger offers his take on how cryptocurrencies like Bitcoin can be affected by central banks.
Canaccord Genuity analyst Eric Zaunscherb discussed this precious metals company's recent request to the government of British Columbia.
The Big Picture for Gold Is Bullish (12/26/2017)
Technical analyst Clive Maund charts gold and finds that although the precious metal is being buffeted by cross currents, the big picture is bullish.
Silver Is a Strong Buy (12/26/2017)
An analysis of silver charts leads technical analyst Clive Maund to conclude that silver should rise soon.
Hunter Diamond, CFA, founder of Diamond Equity Research, profiles a company that he believes offers investors a unique opportunity to invest in the clean, renewable and sustainable transportation market.
Bitcoin, Blockchain and Gold: A Year of Disruption (12/22/2017)
While gold is perceived to have lagged in 2017, the metal is actually up about 10% for the year, notes Frank Holmes, CEO of U.S. Global Investors. In this interview with The Gold Report, Holmes discusses bitcoin and blockchain's dramatic rise, the future of precious metals investing, and companies on his short list to watch.
Adrian Day of Adrian Day Asset Management takes a look at four companies, noting the progress made by three and reflecting on another that is "trying to salvage what it can of its best mine."
A pair of resource companies, along with another couplet of firms, prompted commentary from investment analyst Adrian Day of Adrian Day Asset Management.
Mike Niehuser, an analyst with Scarsdale Equities, provided background on an asset believed to be an "advanced exploration target."
As the year comes to a close, Ralph Aldis, portfolio manager of U.S. Global Investors, reviews some of his precious metals holdings and calls out a handful of companies he believes tax-loss selling has made particularly good values right now.
With multiple gold exploration results coming in from its 100%-owned asset, this company is optimistic about its in-progress PEA on its Nevada property.
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.
David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy.
Andrew Fein, an analyst with H.C. Wainwright & Co., discussed the implications of this biopharmaceutical's recently announced data, which support his "bullish" outlook for the firm's candidate in chronic graft versus host disease.
The CEO of Almaden Minerals, Dr. Morgan Poliquin, sits down with Gerardo Del Real of Resource Stock Digest to discuss the company's Social Impact Assessment for its Ixtaca project in Mexico.
A Pair of Gold Companies Log Changes, Make Progress (12/19/2017)
Adrian Day of Adrian Day Asset Management provides updates on two resource companies, one of which has "exciting recent reports."
With Bitcoin futures now trading on the CBOE, technical analyst Clive Maund expounds on why he believes the Bitcoin market is going to come crashing down.
Tax Loss Silly Season Ending (12/18/2017)
With the year coming to an end and along with it the tax-loss selling season, Bob Moriarty of 321 Gold profiles five companies on his holiday list.
Jack Chan's Weekly Precious Metals Market Update (12/18/2017)
Technical analyst Jack Chan charts the latest movements in the gold and silver markets, noting speculation has reached 'bull market values'.
Technical analyst Clive Maund provides an argument for why two cannabis companies are poised for big gains following the legalization of recreational marijuana in the state of California.
COT Report: Predictably Stomach Churning but Bullish (12/18/2017)
Precious metals expert Michael Ballanger explains why he finds gold stocks "dirt cheap."
The Perfect Gold Stock for Revivalists (12/15/2017)
Technical analyst Clive Maund charts a young gold company that he believes "is going places."
Cannabis Biotech Stock Starting to Advance Again (12/15/2017)
A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock.
New Uranium Assays Improve 'Resource Confidence' (12/14/2017)
David Talbot, an analyst with Eight Capital, outlined recent drill results from this energy company's flagship asset.
Craig Stanley, an analyst with Eight Capital, took a look at the terms and potential of this mining company's prospective transactions in Ontario.
Metallic Minerals Catches the Silver Ring (12/14/2017)
Silver is cheap right now, says Bob Moriarty of 321 Gold, who profiles a company in the Yukon that he says is delivering world-class exploration results.
Exploration is just beginning for this oil and gas E&P with large tracts of prime land in the Permian Basin in Texas.
Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got.
Bitcoin Total Wipeout Alert (12/13/2017)
Technical analyst Clive Maund discusses why he thinks Bitcoin is about to take a dive.
Guyana Shield Is Host to Multiple Gold Deposits (12/12/2017)
As two Guyana projects begin commercial gold production, a new mineral resource estimate is in the works for a third project.
A flagship Nevada project is showing results and the company anticipates commencing commercial production in the first quarter of 2018.
Gold Major to Increase Dividend by 50% in 2018 (12/11/2017)
BMO Capital Markets reported on this miner's outlook for 2018 and beyond.
Jack Chan's Weekly Precious Metals Market Update (12/11/2017)
Technical analyst Jack Chan charts the latest movements in the gold and silver markets.
Cryptojunkies: Beware the Ides of December (12/11/2017)
As Bitcoin futures are set to begin trading next week, precious metals expert Michael Ballanger discusses movements in gold and cryptocurrencies.
Keith Barron Wants to Mine U3O8 'Cheep' (12/11/2017)
More mining companies should follow the example of the garimpeiro miners of Brazil who mine until they fail to make a profit, says Bob Moriarty of 321 Gold, who discusses one gold and one uranium company that may be changing the paradigm.
Drill results from a Nevada lithium project caught the attention of The Critical Investor.
The Critical Investor provides an update on this zinc explorer's latest drill results.
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research.
Cormark Securities provided an update on this company's gold project in central Wyoming.
Biotech Delivers 'Great' Phase 2 Data in NASH (12/07/2017)
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market.
With an advanced project being looked at by potential partners and a newer project producing precious metal results, several analysts rate this precious metals explorer a "Buy."
Multiple projects are showing positive and possible expansions for this gold miner.
Shining a Light on an Out-of-Favor Oil Stock (12/07/2017)
Technical analyst Clive Maund charts an oil and gas explorer that he believes is under the radar of most investors.
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm.
Another Uranium Company to Slash Production in 2018 (12/05/2017)
A BMO Capital Markets report describes the implications of this cutback in production for the uranium market.
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.
Will 2+2=8 For Columbus Gold? (12/05/2017)
Bob Moriarty of 321 Gold discusses why he believes a spinout could be a win for investors.
Technical analyst Jack Chan charts the latest moves in the gold and silver markets, as well as the one-day fluctuations of a gold major.
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation.
As farming becomes increasingly centralized, the need for precise agricultural data grows. Streetwise Reports spoke with Rick Mills, founder of Ahead of the Herd, and Fabrice Taylor, publisher of President's Club, on the fusion of drone-supplied data and data analytics.
Peter Epstein, founder of Epstein Research, evaluates Centenera Mining Corp.'s Esperanza copper-gold porphyry project.
Silver and Gold Bottom Soon (12/01/2017)
Gold and silver are on track to hit a yearly low this December, as they have for the past five years, says Bob Moriarty of 321 Gold, who explains his reasoning and why he welcomes these moves.
The True Meaning of Bitcoin's 'Success' (12/01/2017)
Precious metals expert Michael Ballanger discusses Bitcoin, currency devaluation, and gold and silver.
|"BAR has a treasured land package ripe for future discoveries."|
|"WPM has a diversified asset base and high-margin, scalable business."|
|"DXD timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug."|
|"We anticipate an NI 43-101 resource on RVG's Beartrack by mid-2018."|
|"DRRX has initiated dosing in a Phase IIatrial for DUR-928 in the treatment of primary sclerosing cholangitis."|